Amgen (AMGN) Tops Q4 EPS by 10c, Offers FY Guidance

Amgen (NASDAQ: AMGN) reported Q4 EPS of $2.89, $0.10 better than the analyst estimate of $2.79. Revenue for the quarter came in at $5.97 billion versus the consensus estimate of $5.74 billion.

GUIDANCE:

Amgen sees FY2017 EPS of $11.80-$12.60, versus the consensus of $12.44. Amgen sees FY2017 revenue of $22.3-23.1 billion, versus the consensus of $23.3 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• SLM (SLM) Misses Q2 EPS by 16c; offers guidance
• Summit Therapeutics (SMMT) Reports In-Line Q2 EPS
• Knowles (KN) Tops Q2 EPS by 2c, Offers Guidance